Regarding the pharmacological properties of adrenergic agonists, all of the following statements are correct EXCEPT:

Explanation

## Analysis of Adrenergic Agonist Pharmacology ### Correct Statements (Options A, C, D) **Option A — Phenylephrine (Correct):** - Selective α1-adrenergic agonist with minimal β-adrenergic activity - Causes pure vasoconstriction and increases systemic vascular resistance - Used clinically in hypotension (e.g., spinal anesthesia-induced) and as a nasal decongestant - *(KD Tripathi, Essentials of Medical Pharmacology, 8th ed.)* **Option C — Epinephrine Low-Dose (Correct):** - At very low doses (< 0.5 μg/kg/min), β2-receptors on vascular smooth muscle predominate → vasodilation and net decrease in peripheral vascular resistance - At higher doses (> 2–5 μg/kg/min), α1-mediated vasoconstriction dominates - This dose-dependent vascular response is the classic "epinephrine paradox" — a high-yield NEET PG concept **Option D — Isoproterenol (Correct):** - Non-selective β-agonist (β1 = β2) - Causes tachycardia (β1), bronchodilation (β2), and peripheral vasodilation (β2) - Markedly increases myocardial oxygen demand → contraindicated in acute coronary syndrome and angina - *(Harrison's Principles of Internal Medicine, 21st ed.)* --- ### Incorrect Statement (Option B — THE ANSWER) **Option B — Dobutamine (INCORRECT):** The statement claims dobutamine "does not cause peripheral vasoconstriction." While dobutamine is primarily a **β1-selective agonist**, it also possesses **mild α1-adrenergic activity** (via its (−)-enantiomer). More importantly, the statement's framing is misleading in a second way: dobutamine can actually cause **peripheral vasodilation** via β2 stimulation, not simply "no vasoconstriction." Furthermore, the claim that dobutamine is **universally preferred over dopamine in cardiogenic shock** is an oversimplification. In cardiogenic shock with **severe hypotension**, dopamine (at vasopressor doses) or norepinephrine may be preferred because dobutamine can worsen hypotension through vasodilation. Current guidelines (ESC Heart Failure Guidelines) note that dopamine is not clearly inferior and that the choice depends on hemodynamic profile. | Drug | Receptor Profile | Vascular Effect | |---|---|---| | **Dobutamine** | β1 >> β2 > mild α1 | Net vasodilation (β2 > α1) | | **Dopamine (low dose)** | D1, D2 | Renal/mesenteric vasodilation | | **Dopamine (high dose)** | α1 >> β1 | Vasoconstriction | **Key Point:** **Dobutamine has mild α1 activity AND β2 activity; its net vascular effect is vasodilation, not simply "no vasoconstriction." It is NOT universally preferred over dopamine in all presentations of cardiogenic shock — in severe hypotension, vasopressor support (dopamine or norepinephrine) may be required.** **High-Yield:** Epinephrine dose-response is a classic NEET PG topic: - Low dose (< 0.5 μg/kg/min): β2 > α1 → vasodilation, ↓ SVR - High dose (> 2–5 μg/kg/min): α1 >> β2 → vasoconstriction, ↑ SVR **Clinical Pearl:** Dobutamine is used in cardiogenic shock for **inotropic support** (β1 effect), but it can cause hypotension via vasodilation — making it unsuitable as monotherapy when the patient is already severely hypotensive. *(KD Tripathi, Essentials of Medical Pharmacology, 8th ed.; ESC 2021 Heart Failure Guidelines)*